Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus

Completed · Not applicable · Has a placebo group

Conditions studied: Nephrogenic Diabetes Insipidus

In brief

The purpose of this research study is to determine if two investigational medications will be more effective in decreasing urine output than the currently available and routinely used medications in patients with congenital nephrogenic diabetes insipidus (NDI).

Key facts

Study ID

NCT00478335

Run by

University of Colorado, Denver

People needed

4

Starts

2007-05-01

Expected to finish

2012-10-01

Last updated by the study team

2018-02-12

Who can join

Age: 5 and older, up to 25. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Known diagnosis of Congenital Nephrogenic Diabetes Insipidus (CNDI)
• Age 5 to 25 years
• Normal kidney function
• Post-void residual urine < 200 ml (determined by bladder ultrasound)

You may not qualify if…

• Impaired kidney function
• Known urinary retention or bladder dysfunction
• High blood pressure
• Other significant chronic medical disease (e.g., heart failure, liver disease, etc.)
• Allergy to study drugs

Where it is running

• University of Colorado at Denver and Health Sciences Center — Aurora, Colorado, United States
• University of Aarhus — Aarhus, Denmark

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.